Fig. 2: RETA withdrawal causes a reversal in body weight, adiposity, and fasted blood glucose, with only partial loss of anti-tumor effects in KPCY model of obesity-associated PDAC.

a Percent body weight changes from baseline are reported. b Epididymal white adipose tissue weight was quantified at endpoint. c Fasted blood glucose was quantified at baseline and throughout the study at indicated timepoints until endpoint. d Tumor engraftment or “tumor take” is reported. e Survival curve is plotted as % of mice tumor-free for each group. f Tumor progression over 18 days after injecting KPCY cells was measured by volume recorded using digital caliper. g Endpoint tumor volumes, and (h), tumor weights (normalized to body weights) were quantified. Data are represented as mean ± SEM (N = 10 mice Veh, N = 12 mice RETA, N = 14 mice RETA-w/d). b, g, h Statistical significance was determined by one-way ANOVA with Tukey’s test and is denoted as **P ≤ 0.01, ****P ≤ 0.0001. e Log-rank (Mantel-Cox) test for survival curves (P < 0.0001). c, f Statistical significance was determined by two-way ANOVA with repeated measures using a mixed-effects model and Tukey’s multiple comparison test. c ***P ≤ 0.001, ****P ≤ 0.0001, Veh versus RETA; ^P ≤ 0.05, ^^^^P ≤ 0.0001, Veh versus RETA-w/d; $P ≤ 0.05, P ≤ 0.0001, RETA versus RETA-w/d. f **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, Veh versus RETA; ^P ≤ 0.05, ^^P ≤ 0.01, ^^^P ≤ 0.001, Veh versus RETA-w/d; ^$P ≤ 0.05, ^$$P ≤ 0.01, RETA versus RETA-w/d.